Summary
viremia
VIREMIA
In this feasibility study for a randomized trial of point-of-care VL testing to manage viremia, enrolment was challenging in the context of the COVID-19 pandemic, but once enrolled, follow-up was high. There was good fidelity to the point-of-care intervention, with faster time to results, quicker switching to second-line ART, and fewer clinical visits in the point-of-care arm. However, although not powered for a formal comparison, point estimates of viral suppression at 24 weeks were similar in the point-of-care and standard-of-care arms.